SR 16234

Drug Profile

SR 16234

Alternative Names: SR16234; TAS-108

Latest Information Update: 24 May 2016

Price : $50

At a glance

  • Originator SRI International
  • Developer SRI International; Taiho Pharmaceutical; Tottori University Hospital
  • Class Antineoplastics; Estradiol congeners; Estrenes
  • Mechanism of Action Selective estrogen receptor degraders; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Endometriosis
  • No development reported Breast cancer

Most Recent Events

  • 01 Oct 2015 Tottori University Hospital plans a phase II trial for Endometriosis in Japan (UMIN000019193)
  • 11 Sep 2014 No development reported - Phase-II for Breast cancer in Japan (PO)
  • 11 Sep 2014 No development reported - Phase-II for Breast cancer (Late-stage disease, Metastatic disease) in Russia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top